Ethylene glycol monopropyl ether (EGPE) is a colorless, flammable liquid with a slightly sweet odor. It is a solvent used in various applications, including paint thinners, coatings, and adhesives. EGPE is synthesized by reacting ethylene oxide with propanol. The compound is readily absorbed through the skin, and can cause irritation and allergic reactions. It is also known to be a potential reproductive toxicant. EGPE is studied due to its widespread use and potential health risks. Research focuses on its environmental fate, toxicity, and potential for bioaccumulation in various organisms. '
| ID Source | ID |
|---|---|
| PubMed CID | 17756 |
| CHEMBL ID | 3189002 |
| SCHEMBL ID | 23209 |
| MeSH ID | M0128245 |
| Synonym |
|---|
| LS-13094 |
| 2-propoxy-ethanol |
| ethanol, 2-propoxy- |
| ethylene glycol monopropyl ether |
| monopropyl ether of ethylene glycol |
| brn 1731983 |
| 2-(propyloxy)ethanol |
| n-propyl oxitol glycol |
| ethylene glycol mono propyl ether |
| propyl cellosolve |
| ethylene glycol mono-n-propyl ether |
| hsdb 6499 |
| ai3-30229 |
| einecs 220-548-6 |
| ektasolve ep |
| ethylene glycol n-propyl ether |
| propoxyethanol |
| n-propoxyethanol |
| ethylene glycol propyl ether |
| 2807-30-9 |
| 2-propoxyethanol |
| propyl glycol |
| E0514 |
| NCGC00249145-01 |
| EN300-69935 |
| unii-tf513kwz2y |
| ec 220-548-6 |
| tf513kwz2y , |
| NCGC00256983-01 |
| cas-2807-30-9 |
| dtxsid1027500 , |
| dtxcid707500 |
| tox21_303034 |
| tox21_201994 |
| NCGC00259543-01 |
| A819313 |
| 2-propoxyethan-1-ol |
| FT-0626336 |
| AKOS009159123 |
| ethylene glycol monopropyl ether [hsdb] |
| SCHEMBL23209 |
| ethyleneglycol monopropyl ether |
| 2-propoxy-1-ethanol |
| W-107077 |
| eastman ep |
| 3-oxa-1-hexanol |
| ethyleneglycol mono-n-propyl ether |
| 2-propyloxyethanol |
| CHEMBL3189002 |
| mfcd00072645 |
| ethylene glycol monopropyl ether, reagentplus(r), 99.4% |
| ethylene glycol monopropyl ether, vetec(tm) reagent grade, 99% |
| E77170 |
| Q1371478 |
| 2-(1-propyloxy) ethanol |
| 2-hydroxyethyl propyl ether |
| glycol monopropyl ether |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The oral LD50 in rats was 3089 and 9456 mg/kg EGPE and EGPEA, respectively." | ( Comparative acute and subchronic toxicity of ethylene glycol monopropyl ether and ethylene glycol monopropyl ether acetate. Katz, GV; Krasavage, WJ; Terhaar, CJ, 1984) | 0.53 |
| " Therefore, predicted dose-response curves for rat could be used to set a point of departure for deriving safe exposure limits in human risk assessment." | ( The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Blaauboer, BJ; de Jong, E; Louisse, J; Piersma, AH; Rietjens, IM; van de Sandt, JJ; Verwei, M; Woutersen, RA, 2010) | 0.36 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In vitro toxicity tests provide in vitro concentration-response curves for specific target cells, whereas in vivo dose-response curves are regularly used for human risk assessment." | ( The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Blaauboer, BJ; de Jong, E; Louisse, J; Piersma, AH; Rietjens, IM; van de Sandt, JJ; Verwei, M; Woutersen, RA, 2010) | 0.36 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.12) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||